Prevalence and coexistence of type 2 inflammatory diseases
Author
Publication date
2024ISSN
2045-7022
Abstract
Background: Type 2 inflammation has been described as a pathophysiological basis common to some diseases, such as atopic dermatitis (AD), chronic rhinosinusitis with nasal polyps, and asthma (CRSwNP). Objective: The present study used population-based prevalence in Catalonia to analyse the coexistence of type 2 inflammatory diseases in patients primarily diagnosed with the above mentioned conditions. Results: We found a high degree of coexistence of type 2 inflammatory diseases among these patients, with the prevalence being higher in the severe forms, except for AD. For the severe forms of primary diseases, the proportion of patients with coexisting type 2 inflammatory diseases (severe or non-severe) was 16.2% for AD, 19.8% for asthma, and a striking 62.4% for CRSwNP. This patient population has the highest proportion of coexisting type 2 inflammatory diseases, both severe (48.9%) and non-severe (13.5%). Conclusion: Our findings have significant implications for the management of patients with AD, asthma, and CRSwNP.
Document Type
Article
Document version
Published version
Language
English
Subject (CDU)
61 - Medical sciences
616.2 - Pathology of the respiratory system. Complaints of the respiratory organs
Keywords
Pages
4
Publisher
Wiley
Collection
14; 6
Is part of
Clinical and Translational Allergy
Citation
Mora, Toni; Sánchez-Collado, Irene; Muñoz‐Cano, Rosa [et al.]. Prevalence and coexistence of type 2 inflammatory diseases. Clinical and Translational Allergy, 2024, 14(6), e12376. Disponible en: <https://onlinelibrary.wiley.com/doi/10.1002/clt2.12376>. Fecha de acceso: 16 dic. 2024. DOI: 10.1002/clt2.12376
Note
Sanofi; University of Catalonia Real‐WordEvidence Chair
This item appears in the following Collection(s)
Rights
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, pro-vided the original work is properly cited.© 2024 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/


